Related Experiment Videos
Prevention of etretinate-induced craniofacial malformations by vitamin B6 in the rat
1Department of Pedodontics, University of Gothenburg, Sweden.
Insights
Vitamin B6 (pyridoxine) may prevent birth defects caused by etretinate in pregnant rats. This vitamin reduced the severity of malformations like facial clefts and developmental anomalies.
Area of Science:
- Teratology
- Developmental Toxicology
- Nutritional Biochemistry
Background:
- Etretinate is a known teratogen causing significant congenital malformations.
- Understanding protective agents against drug-induced developmental toxicity is crucial.
Purpose of the Study:
- To investigate the preventive potential of vitamin B6 against etretinate-induced teratogenesis.
- To assess the efficacy of vitamin B6 in mitigating specific malformations.
Main Methods:
- Pregnant Sprague-Dawley rats were administered etretinate (10 mg/kg) at embryonic day 8.5.
- Vitamin B6 was administered via intramuscular injection at embryonic days 7.5 and 8.5.
- Evaluated the incidence and severity of fetal malformations.
Main Results:
- Vitamin B6 significantly reduced the occurrence and severity of facial clefts.
- Observed a decrease in micrognathia, meningocele, and microtia.
- Reduced incidence of blood vessel anomalies in the treated group.
Conclusions:
- Vitamin B6 demonstrates a protective effect against etretinate-induced developmental abnormalities.
- Early or concurrent administration of vitamin B6 may suppress teratogenic effects.
- Vitamin B6 shows promise as a potential countermeasure for etretinate teratogenicity.
Abstract:
The preventive effect of vitamin B6 on etretinate-induced malformations in pregnant Sprague-Dawley rats was studied. The etretinate-induced malformation was produced by intraperitoneal administration of 10 mg/kg etretinate at embryonal day 8.5. Vitamin B6 was administered as intramuscular injections at embryonal day 7.5 and 8.5. Vitamin B6 reduced the number and severity of facial clefts, micrognatia, meningocele, microtia and blood vessel anomalies. It is suggested that vitamin B6 induces suppressive effects on etretinate-induced teratogenesis when administered before or at the same time as the teratogen.